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During chronic liver injury, hepatic stellate cells (HSC) are activated and proliferate, which causes excessive
extracellular matrix (ECM) deposition, leading to scar formation and fibrosis. Medicinal plants are gaining popularity
as antifibrotic agents, and are often safe, cost-effective, and versatile. This review aims to describe the protective role
and mechanisms of medicinal plants in the inhibition of HSC activation and ECM deposition during the pathogenesis
of liver fibrosis. A systematic literature review on the anti-fibrotic mechanisms of hepatoprotective plants was
performed in PubMed, which yielded articles about twelve relevant plants. Many of these plants act via disruption
of the transforming growth factor beta 1 signaling pathway, possibly through reduction in oxidative stress. This
reduction could explain the inhibition of HSC activation and reduction in ECM deposition. Medicinal plants could
be a source of anti-liver fibrosis compounds.Introduction
Liver fibrosis is caused by inappropriate tissue repair via
connective tissue deposition, which results from chronic
liver injuries, including those from alcohol, chronic viral
hepatitis, autoimmune diseases, parasites, metabolic dis-
eases, and toxins or other drugs [1]. When fibrosis is not
controlled, it can progress into cirrhosis. Cirrhosis was
previously considered to be irreversible, but some studies
suggest that fibrosis and cirrhosis could be reversible [2].
Liver fibrosis is a public health problem that results
in significant morbidity and mortality [3]. Hundreds of
thousands of people worldwide suffer from cirrhosis, par-
tially because of the obesity pandemic combined with the
high incidence of alcohol abuse and viral hepatitis [4].
Chronic viral hepatitis (B and C), alcoholic liver disease,
and nonalcoholic fatty liver disease are the three most
common causes of liver cirrhosis [5]. The prevalence of
chronic liver diseases is predicted to increase, partially
owing to the rising prevalence of obesity and metabolic
syndrome, especially in developed countries [6].* Correspondence: cruzvegade@gmail.com
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unless otherwise stated.The pathogenesis of liver fibrosis is complex and varies
among different kinds of hepatic injuries. Usually after
acute liver damage, parenchymal cells are regenerated to
replace the necrotic and apoptotic cells. This regenera-
tive process is associated with an inflammatory response
and a limited deposition of extracellular matrix (ECM).
When the liver is subjected to chronic injury, the regen-
erative response fails and hepatocytes are replaced with
abundant ECM, which is mainly composed of collagen
types I, III, and IV; fibronectin; elastin; laminin; and pro-
teoglycans [7]. Hepatic stellate cells (HSC) are the main
source of ECM [8].
There is no standard treatment for liver fibrosis [7],
but a reduction in liver injury events, such as cessation
of alcohol intake or successful viral hepatitis treatment
can control fibrosis. Nevertheless, these actions are often
insufficient to avoid eventual progression to cirrhosis in
the vast majority of patients [9]. Although important
advances have been made in understanding the pathogen-
esis of hepatic fibrosis over the past 20 years, efficient
antifibrotic drugs have yet to be developed. There are two
ways by which medicinal plants and their bioactive
compounds and extracts could reduce liver fibrosis: viahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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deposition (Figure 1). Liver fibrosis treatment should take
into account the versatility of its pathogenesis and should
act upon all pathways involved, beginning with HSC
activation and ECM deposition.
Medicinal plants are often safe, cost-effective, and versa-
tile, and are therefore popular potential antifibrotic agents.
This review aims to describe the role of some hepato-
protective plants in the inhibition of HSC activation and
ECM deposition in the pathogenesis of liver fibrosis.
These plants include: Curcuma longa, Silybum marianum,
Ginkgo biloba, Salvia miltiorrhiza, Glycyrrhiza glabra,
Scutellaria baicalensis, Bupleurum falcatum, Phyllanthus
species, Berberis aristata, Ginseng species, Andrographis
paniculata, and Coffea species.
Literature inclusion criteria
The 12 plant species were selected because of their
known hepatoprotective activities. A three-step progres-
sive searching method was applied using PubMed. In
each of the steps, only pertinent articles were selected.
First, a global search on the liver activity of each plant
species was undertaken using the keywords “liver” and
“plant species name”. The antifibrotic activities were
classified under two different pathways: inhibition of HSC
activation and suppression of ECM deposition. Bioactive
compounds and extracts from every reviewed species were
selected. Second, a more advanced search was performed
using the terms “liver fibrosis” and “plant species name or
bioactive extract name or bioactive compound name”. Fi-
nally, a search on the antifibrotic mechanisms of each
species was performed using the terms “hepatic stellate
cells activation”, “extracellular matrix”, “collagen”, and
“plant species name or bioactive extract name or bioactive
compound name”.Figure 1 Antifibrotic medicinal plants targeting HSC activation and E
1: C. longsa, S. marianum, G. biloba, S. miltiorrhiza, G. glabra, S. baicalensis, B. fa
Coffea species. 2: C. longa, S. marianum, G. biloba, S. miltiorrhiza, G. glabra, S. b
Coffea species.Inhibition of hepatic stellate cell activation
Role of hepatic stellate cell activation in the pathogenesis
of liver fibrosis
HSC activation, which includes initiation and perpetu-
ation, is an early event in liver fibrogenesis. The activation
of HSCs converts normal, quiescent vitamin A-rich cells
into myofibroblast-like cells characterized by proliferation,
chemotaxis, fibrogenesis, contractility, matrix degradation,
retinoid loss, and white blood cell chemoattractant/cyto-
kine release [10-14].
HSCs are initiated when gene expression and phenotype
changes render the quiescent cells responsive to other cy-
tokines and stimuli [10,12]. Several paracrine stimuli from
damaged hepatocytes and other neighboring cell types,
such as Kupffer cells, platelets, sinusoidal endothelium,
and immune cells initiate the activation of HSCs [15].
Transforming growth factor beta 1 (TGF-β1), platelet-
derived growth factor (PDGF), and epidermal growth
factor (EGF) mediate platelet stimuli [15,16]. By produ-
cing fibronectin and activating latent TGF-β1, injured
endothelial cells provoke HSC activation. Kupffer cells
are important sources of paracrine stimuli for HSCs
because they express TGF-β1, transforming growth fac-
tor alpha (TGF-α), reactive oxygen species, and lipid
peroxides. These Kupffer cell paracrines lead to matrix
synthesis, cell proliferation, and the release of retinoids
[15] and matrix metalloproteinase (MMP)-9 [17] for
collagen synthesis through the activation of latent TGF-β1
[18]. Kupffer cells also inhibit fibrogenesis via the produc-
tion of anti-inflammatory interleukin-10 and nitric oxide
(NO), which decrease collagen synthesis, increase collage-
nase production, and reduce cell proliferation and con-
tractility [15]. All these stimuli trigger important changes
in the composition of ECM, especially an increase in type
I and III fibril-forming collagens and fibronectin [10]. ThisCM deposition. HSC: hepatic stellate cells, ECM: extracellular matrix,
lcatum, Phyllanthus species, B. aristata, Ginseng species, A. paniculata, and
aicalensis, B. falcatum, Phyllanthus species, B. aristata, Ginseng species, and
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fibrogenic stimuli, which further exacerbate fibrosis [12].
During HSC activation, regulatory pathways like epi-
genetic regulation of nuclear factor kappa B (NF-κB) and
reduction in peroxisome proliferator-activated receptor
gamma (PPARγ) expression modulate the expression of
many genes, such as type I collagen (α1 and α2 chains),
smooth muscle α-actin, TGF-β1, TGF-β receptors (TβRI
and II), MMP-2, and tissue inhibitor of metalloproteinases
(TIMP)-1 and −2 [10,12].
Perpetuation of HSC activation results in maintenance
of the activated phenotype and therefore the generation
of fibrosis [15]. Scars are formed through changes in
HSC behavior, like proliferation, fibrogenesis, contractility,
chemotaxis, retinoid loss, white blood cell chemoattract-
ant/cytokine release, and matrix degradation [12].
Cell proliferation further promotes liver fibrosis by
increasing the number of collagen-producing cells. Several
mitogens have been identified to be responsible in liver
fibrosis, namely PDGF; vascular endothelial growth factor
(VEGF); thrombin and its receptor, EGF; TGF-α; keratino-
cyte growth factor; insulin-like growth factor; protease-
activated receptor agonists; basic fibroblast growth
factor; monocyte chemotactic factor; interleukin-6; con-
nective tissue growth factor (CTGF); endothelin-1; and
angiotensin-II [11,12,19].
HSCs migrate towards injured areas in the liver, which
increases the fibrogenic response at a specific site via
mediation of several chemoattractants, including PDGF,
monocyte chemoattractant protein-1 (MCP-1), and che-
mokine receptor CXCR3 [10,12].
Fibrogenesis is defined as increased fibrotic matrix
production, especially that of collagen type I [12]. TGF-β1,
produced by HSCs and other neighboring cell types like
Kupffer cells, sinusoidal endothelial cells, bile duct epithe-
lial cells, and hepatocytes [11], is a potent fibrogenic signal
[20] as it increases the production of collagen I and other
matrix constituents like fibronectin and proteoglycans
[12,21]. These effects are induced by the interaction
between TGF-β1 and the membrane receptor complex
formed by TβRI and TβRII, leading to the phosphoryl-
ation of intracellular mediators, namely Smad proteins.
Smad proteins are divided into three groups: receptor-
activated Smad (R-Smad), common-Smad (Co-Smad)
and inhibitory-Smad (I-Smad). Phosphoylated R-Smad
(Smad1, Smad2, Smad3, Smad5 and Smad8) dissociate
from anchoring proteins and associate with Co-Smad
(Smad4). R-Smad-Co-Smad complexes are transported
into the nucleus where they act as transcription fac-
tors. This cascade is inhibited by I-Smad (Smad6 and
Smad7) [20]. CTGF (through TGF-β-dependent and -inde-
pendent pathways), endothelin-1, leptin, and angioten-
sin II have also been reported as fibrogenic factors for
HSCs [11,22].Stellate cell contractility is associated with portal hy-
pertension and may lead to the collapse and shrunken
state of cirrhotic livers [23]. The increased expression of
contractile proteins, smooth muscle α-actin, and smooth
muscle myosins via calcium-dependent and calcium-
independent pathways mediate the contractility of HSCs
[11]. Endothelin-1, NO, angiotensinogen II, eicosanoids,
atrial natriuretic peptide, somatostatin, and carbon mon-
oxide are some of the signals that contribute to the con-
tractile phenotype of HSCs [12]. Because HSCs are so
important to fibrogenesis, the inhibition of HSC activa-
tion is a possible therapeutic approach to reversing liver
fibrosis [1,4]. For instance, PPARγ ligands [24], interferon
gamma (IFNγ) [25], and antioxidants [26] reduce liver
fibrosis by inhibiting TGF-β1 expression and therefore
HSC activation.
Hepatic stellate cell activation as a target of antifibrotic
medicinal plants
All the reviewed medicinal plants were shown to suppress
HSC activation. Since the activation of HSCs occurs via a
complex network of signaling pathways, different targets
have been investigated to explain the antifibrotic activity
(Table 1).
Activation of TGF-β1/Smad signaling is one of the most
important profibrogenic pathways [20]. The disruption of
this pathway is a common feature of all of the reviewed
antifibrotic plants. Down-regulation of the expression of
TGF-β1 and its receptors, TβRI and II, and modulation of
its mediators Smad 2, 3, and 7 has been observed via
curcumin [28,30,32,34,37,38] and compounds from S.
miltiorrhiza [49,66,70,75-78,83,88-91,98], G. glabra [102,103]
and Coffea species [120-128]. Several mechanisms have
been identified for the inhibition of TGF-β1 signaling via
curcumin, like PPARγ activation and antioxidation. Cur-
cumin inhibits NF-κB [27], leptin [39], advanced glycation
end-product (AGE) [33], low-density lipoprotein (LDL)
[40,41], and insulin [42] mediated HSC activation by sti-
mulating PPARγ activity and inducing de novo synthesis
of glutathione [27,33,39 − 42]. Inhibition of NF-κB and
stimulation of PPARγ activities are also observed in G.
biloba extract [56,57], 18α glycyrrhizin [101], glycyrrhetinic
acid [104], and baicalin [107]. Salianic acid B and salviano-
lic acid B inhibited p38 mitogen-activated protein kinases
[88,90,94,99,100] and extracellular signal-regulated kinases
(ERK) signaling [46,90,92,94,96,98,100] by blocking phos-
phorylation of mitogen-activated protein kinase kinase 3/6,
inhibiting expression of myocyte enhancer factor-2 [94],
and suppressing phosphorylation of mitogen-activated
protein kinase kinase [96,100], in activated HSCs. Further,
salvianolic acid B reduced hepatic fibrosis by disrupting
angiotensin II signaling via down-regulation of angioten-
sin II receptor type 1, ERK, and c-Jun phosphorylation
[98]. Andrographolide from A. paniculata decreased the
Table 1 Inhibitory mechanisms of hepatic stellate cell activation via medicinal plants
Medicinal plants Bioactive compounds/extracts Targeted fibrogenic pathways
C. longa [27-46] Curcumin TGF-β1a; CTGFb; PDGFc; TGF-αd; VEGFe; AGEf; leptin;
LDLg; insulin; HIF-1αh; PGFi
S. marianum [47-54] Silymarin TGF-β1a; CTGFb
G. biloba [55-60] G. biloba extract, EGb761 TGF-β1a; CTGFb; PAFj; endothelin-1
S. miltiorrhiza [46,49,61-100] Water extract of S. miltiorrhiza; salvianolic acid A;
salvianolic acid B; magnesium lithospermate B;
tanshinone IIA; IH764-3
TGF-β1a; CTGFb; PDGFc; MCP-1k; endothelin-1;
angiotensin II
G. glabra [101-104] Glycyrrhizin; 18α-glycyrrhizin; glycyrrhizic acid TGF-β1a
S. baicalensis [105-107] Baicalin TGF-β1a
B. falcatum [32,108,109] Saikosaponin-A; saikosaponin-D TGF-β1a
Phyllanthus species [110,111] Ethanol extract of P. rheedii Wight; ethanol
extract of P. niruri
TGF-β1a
B. aristata [112-114] Berberine TGF-β1a
P. notoginseng [105,115-118] Ginsenoside Rg1; ginsenoside Rb1; P. notoginseng
saponins; 25-OCH3-PPD
TGF-β1a; PDGFc
A. paniculata [119] Andrographolide TGF-β1a
Coffea species [120-130] Caffeine; 1,7-dimethylxanthine; theophylline;
theobromine
TGF-β1a; CTGFb; VEGFe; PDGFc
aTransforming growth factor beta 1, bconnective tissue growth factor, cplatelet derived growth factor, dtransforming growth factor alpha, evascular endothelial
growth factor, fadvance glycation end-product, glow-density lipoprotein, hhypoxia-inducible factor-1α, iplacental growth factor, jplatelet activate factor, kmonocyte
chemotactic protein-1.
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c-Jun N-terminal kinases and the ERK phosphorylation
cascade [119].
HSC proliferation is mediated by different proteins, in-
cluding PDGF, CTGF, VEGF, and TGF-α through various
signal molecules, such as ERK and focal adhesion kinase
(FAK) [12]. Some plant extracts target these growth fac-
tors and their respective signaling pathways to reduce
the proliferative response of HSCs. CTGF is inhibited by
curcumin [34,36], silymarin [54], G. biloba extract [59],
Salvia extract [49,76], and caffeine [120,128-130] via in-
hibition of TGF-β signaling. Moreover, curcumin was
shown to reduce the promoter activity of CTGF and
suppress its gene expression by reducing NF-κB activity
[36]. NF-κB was inhibited by suppression of ERK activity
and suppression of Toll like receptor-4 gene expression
via PPARγ activation [36].
PDGF and its receptor PDGF-βR were found to be
down-regulated by curcumin [35,37], salvianolic acid
A [63] and B [92], coffee [123], and ginsenoside Rg1
[116]. Ginsenoside Rg1 down-regulated the expression
of PDGF-βR by reducing NF-κB activity [116]. Different
bioactive compounds from S. miltiorrhiza reduced HSC
proliferation. The monomer IH764-3 inhibited HSC pro-
liferation by down-regulating FAK and ERK expression
[64,65,80], while salvianolic acid B attenuated PDGF-
induced c-Jun N-terminal kinases, p38, and protein kinase
C delta phosphorylations [95].
VEGF and its receptors were suppressed by curcumin
[45] and coffee [122], which could also explain theiramelioration of angiogenesis in the fibrotic liver. Add-
itionally, curcumin reduced TGF-α levels [43].
Cyclins, and cyclin inhibitors, are essential proteins for
the control of the cell cycle, and potential therapeutic
targets for inhibiting HSC proliferation. The cyclin D1
gene was down-regulated by curcumin through PPARγ
activation [30]. Inhibition of HSC proliferation by salvia-
nolic acid A was mediated by the induction of cell cycle
inhibitory proteins p21 and p27, down-regulation of
cyclins D1 and E, and suppression of protein kinase B
phosphorylation [63].
Medicinal plants also regulate the contraction of HSCs.
For example, salvianolic acid B lowered portal pressure
and attenuated the contraction of HSC by inhibiting
the Ras homolog family member A signaling pathway
[97] and decreasing the HSC free calcium ion concentra-
tion [93].
Reduction in extracellular matrix deposition
Role of extracellular matrix deposition in the pathogenesis
of liver fibrosis
Liver fibrosis is a dynamic process in which the equi-
librium between ECM synthesis and degradation is
impaired [11]. HSCs, neutrophils, and macrophages
are the main cellular contributors to ECM degradation
[1], while HSCs, portal myofibroblasts, bone-marrow-
derived cells, and the epithelial–mesenchymal transition
are responsible for ECM synthesis [14]. All these cells in-
volve several molecular effectors such as matrix proteins,
MMPs and TIMPs.
Duval et al. Chinese Medicine  (2014) 9:27 Page 5 of 11During fibrogenesis, several ECM proteins, especially
collagens type I, III, and IV; proteoglycans; laminin; and
fibronectin are over-expressed by activated HSCs and
other cells, which results in pathological scar formation
[131]. Accumulation of ECM not only depends on up-
regulation of ECM production, but also on MMP–TIMP
expression [132,133]. In the early phases of liver injury,
HSCs transiently express MMP-3 and MMP-13, which is
a matrix-degrading phenotype. In the later stages of liver
injury, the inhibition of fibrillar liver collagen degrad-
ation prevails over ECM synthesis, as evidenced by in-
creased TIMP-1 expression, which leads to a decrease in
collagen degradation by MMP-1 and MMP-13 [133].
TIMP-1 was found to protect HSCs from apoptosis [134].
Regulation of the plasminogen activation system, includ-
ing enhanced production of the urokinase-plasminogen
activator (uPA) and uPA receptor and modulation of
plasminogen activator inhibitor type 1 (PAI-1), is another
method by which HSCs regulate the ECM [135-137].
Macrophages also take part in matrix breakdown [9,138],Table 2 Inhibitory mechanisms of extracellular matrix deposi




S. marianum [47,48,50,51,160-165] Silymarin; silibinin (silybin)
G. biloba [55-59,166-169] G. biloba extract; EGb761
S. miltiorrhiza
[46,49,65,66,75-91,94,96,98,99,170-179]
Salvianolic acid A; salvianolic acid B;
salvianic acid A; salianic acid B;
IH764-3; magnesium; lithospermate B
tanshinone IIA; SMND-309
G. glabra [102-104,180,181] Glycyrrhizin; glycyrrhetinic acid;
glycyrrhizic acid
S. baicalensis [105,106] Baicalin
B. falcatum [32,108,182] Saikosaponin A; saikosaponin D
Phyllanthus species [111,183] P. amarus extract; ethanol extract
of P. niruri
B. aristata [114] berberine
P. notoginseng
[105,115,117,118,184,185]
P. notoginseng saponins; ginsenoside
Rb1; red ginseng extract; 25-OCH3-PP
Coffea species
[122,124-126,128,186-189]
Decaffeinated coffee; normal coffee;
1,7-dimethylxanthine; caffeine;
chlorogenic acid
↓: inhibitory effect, ↑: increased effect, aextracellular matrix, bmatrix metalloproteina
1, eurokinase-plasminogen activator.since macrophages produce MMPs, like MMP-13
[139,140] and MMP-9 [141,142] through the mitogen-
activated protein kinase and NF-κB pathways [143].
The dynamic process of matrix degradation and syn-
thesis could be a therapeutic target to reversing liver fi-
brosis and restoring normal liver architecture [4,11,144].
Indeed, MMP-8 cloned into an adenoviral vector re-
versed fibrosis in cirrhotic animal livers [145]. In vivo re-
duction of liver fibrosis has also been observed with
similar therapeutic approaches involving MMP-1 [146],
TIMP-1 scavengers [147], and uPA [148].
Extracellular matrix deposition as a target of antifibrotic
medicinal plants
All of the reviewed medicinal plants, except A. panicu-
lata, were shown to reduce ECM deposition. Plant com-
pound targets include multiple components of the ECM,
such as collagen species, laminin, and fibronectin, as
well as MMPs, TIMPs, and the plasminogen activation
system (Table 2).tion via medicinal plants
Mechanisms of reduction in ECM deposition
↓ECMa proteins ↑MMPsb ↓TIMPsc Plasminogen
activation system















Collagen type I; collagen
type III; laminin; hyaluronic
acid; collagen type IV
MMP-1 TIMP-1 _
;
Collagen type I; collagen
type III; hyaluronic acid;
collagen type IV; laminin
MMP-13 TIMP-1 ↓PAI-1d; ↑uPAe
Collagen type I; collagen
type III
MMP-9 _ _
Collagen type I; collagen
type III; hyaluronic acid
collagen type IV
_ TIMP-1 _
Collagen type I; hyaluronic
acid; collagen type IV;
laminin
_ _ _
Collagen type I MMPs TIMPs _
_ MMP-2 _ _
D
Collagen type I; collagen
type III; hyaluronic acid;
collagen type IV
MMP-13 TIMP-1 ↓PAI-Id
Collagen type I _ _ _
Collagen type III
se, ctissue inhibitor of metalloproteinase, dplasminogen activator inhibitor type
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like GbE761, salvianolic acids A and B, salianic acid B, S.
miltiorrhiza extracts, magnesium lithospermate B, tanshi-
none IIA, monomer IH764-3, glycyrrhizin, glycyrrhetinic
acid, glycyrrhizic acid, baicalin, saikosaponin A and D,
P. amarus extracts, berberine, P. notoginseng saponins,
ginsenoside Rb1, red ginseng extract, conventional and
decaffeinated coffee, 1,7-dimethylxanthine, caffeine, and
chlorogenic acid, reduced hepatic collagen content by
down-regulating hepatic expression of type I and III col-
lagen and/or decreasing the serum levels of type III pro-
collagen and type IV collagen. Fibronectin expression
was reduced by curcumin [37]. Serum levels of laminin
and hyaluronic acid were lowered by curcumin, G.
biloba extracts like GbE761, salvianolic acid B, SMND-
309, baicalin, saikosaponin D, and P. notoginseng sapo-
nins. Expression of MMPs, like MMP-1, −2, −7, −9,
and −13, were enhanced by curcumin [30,43,154,157],
G. biloba extract [166], S. miltiorrhiza [66,77], salianic
acid B [90], monomer IH764-3 [178], glycyrrhizin [181],
baicalin [105], berberine [114], and P. notoginseng sapo-
nins [185], which stimulate the degradation of collagen
deposits. However, MMPs have been observed to be
downregulated after treatment with curcumin [158], sily-
marin [50,51], S. miltiorrhiza [172], salvianolic acid B
[175], ethanol extract of P. niruri [111], ginsenoside Rb1
[117], conventional and decaffeinated coffee, and caffeine
[125,126,128]. Tissue remodeling induced by MMPs pro-
gresses liver fibrosis, so reducing MMP expression could
be an antifibrotic strategy. Moreover, curcumin, silymarin,
G. biloba extract, S. miltiorrhiza, monomer IH764-3, bai-
calin, P. amarus extract, P. notoginseng saponins, and
ginsenoside Rb1 inhibited the expression of TIMP-1
and −2. Salvianic acid A (danshensu) and red ginseng
extract down-regulated the expression of PAI-1 [173,184],
while salvianic acid A up-regulated uPA expression [173].
Since ECM proteins, MMPs, and TIMPS are over-
expressed when HSCs are activated, the inhibition of HSC
activation and proliferation is the main method by which
plants can suppress ECM deposition. The antifibrotic
mechanism is mainly the result of down-regulating the
TGF-β1/Smad signaling pathway.
Highlights
Inhibition of HSC activation and subsequent ECM de-
position via medicinal plants is the result of TGF-β1/
Smad signaling disruption. The down-regulation of TβRI
and II and modulation of Smads suggests a common
mechanism upstream to the pathway affected by the
plants. Since oxidative stress is involved in the activation
of HSCs, antioxidative properties could be the common
mechanism by which the plants inhibit HSC activation
and ECM deposition.The antifibrotic properties of medicinal plants have
mainly been observed in liver fibrosis models in vitro
and in vivo. Clinical studies are sparse and mainly re-
cruited chronic hepatitis B and C patients to assess the
hepatoprotective effects of medicinal plants. Silymarin,
glycyrrhizin, and S. miltiorrhiza have been somewhat
successfully tested. Glycyrrhizin treatment induced a
decrease in alanine transaminase and maintenance and
improvement of necroinflammation in chronic hepatitis
C nonresponders, and those patients unlikely to respond
to interferon therapy when they receive at least three
injections weekly over the course of 4, 22, or 52 weeks
[190-193]. Since glycyrrhizin had no effect on hepatitis C
RNA [190], investigation of the hepatoprotective me-
chanisms, such as inhibition of HSC activation and ECM
deposition, is necessary.
Salvia injection and salvianolic acid B, have been tested
in patients infected with hepatitis B. Salvianolic acid B,
administrated over 6 months, reversed liver fibrosis and
inflammation more effectively than IFNγ in patients with
hepatitis B, as suggested by significant improvement in
serum hyaluronic acid, laminin, type IV collagen, and
procollagen III peptide as compared with the IFNγ
group [194]. The same results, as well as decreased levels
of alanine transaminase and aspartate transaminase were
observed in fibrotic and cirrhotic patients infected with
hepatitis B virus who were treated with Salvia injections
over 45 [195] or 60 days [196]. However, another study on
chronic hepatitis B patients treated with S. miltiorrhiza
injection showed improvements only in symptoms,
physical signs, and liver functions, not antifibrotic ef-
fects. Therefore, additional clinical studies are required
to understand the effect of S. miltiorrhiza injection on
liver fibrosis [197].
Clinical studies on silymarin administration for the
treatment of hepatitis C were inconclusive. Silymarin
has antiviral activity and has been associated with reduced
progression from fibrosis to cirrhosis in advanced hepatitis
C patients [198]. However, it has low oral bioavailability at
0.73% in rat plasma [199-201] and has not always been
associated with hepatic improvement. For example, it was
not effective in patients with chronic viral hepatitis C
infection that who also unsuccessfully treated with
interferon-based therapy [202].
Besides HSC activation and ECM deposition, other
events like oxidative stress, inflammation, and im-
mune responses are involved in the fibrogenic response
[10,11,13,14]. These pathways are potential targets that
could help reduce hepatic fibrosis. Nevertheless, several
medicinal plants have been shown to inhibit HSC activa-
tion and ECM deposition during liver fibrosis.
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